Switch to:
Also traded in: Argentina, Brazil, France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.44
LLY's Cash-to-Debt is ranked lower than
75% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. LLY: 0.44 )
Ranked among companies with meaningful Cash-to-Debt only.
LLY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: 0.72 Max: N/A
Current: 0.44
Equity-to-Asset 0.34
LLY's Equity-to-Asset is ranked lower than
83% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. LLY: 0.34 )
Ranked among companies with meaningful Equity-to-Asset only.
LLY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.23  Med: 0.45 Max: 0.67
Current: 0.34
0.23
0.67
Interest Coverage 18.04
LLY's Interest Coverage is ranked lower than
66% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.31 vs. LLY: 18.04 )
Ranked among companies with meaningful Interest Coverage only.
LLY' s Interest Coverage Range Over the Past 10 Years
Min: 17.77  Med: 21.38 Max: 35.18
Current: 18.04
17.77
35.18
Piotroski F-Score: 6
Altman Z-Score: 3.37
Beneish M-Score: -2.76
WACC vs ROIC
2.95%
11.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 16.30
LLY's Operating Margin % is ranked higher than
70% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. LLY: 16.30 )
Ranked among companies with meaningful Operating Margin % only.
LLY' s Operating Margin % Range Over the Past 10 Years
Min: -6.29  Med: 21.98 Max: 28.28
Current: 16.3
-6.29
28.28
Net Margin % 11.12
LLY's Net Margin % is ranked higher than
64% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. LLY: 11.12 )
Ranked among companies with meaningful Net Margin % only.
LLY' s Net Margin % Range Over the Past 10 Years
Min: -10.17  Med: 16.88 Max: 21.97
Current: 11.12
-10.17
21.97
ROE % 16.91
LLY's ROE % is ranked higher than
73% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. LLY: 16.91 )
Ranked among companies with meaningful ROE % only.
LLY' s ROE % Range Over the Past 10 Years
Min: -20.47  Med: 26.51 Max: 53.25
Current: 16.91
-20.47
53.25
ROA % 6.39
LLY's ROA % is ranked higher than
61% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. LLY: 6.39 )
Ranked among companies with meaningful ROA % only.
LLY' s ROA % Range Over the Past 10 Years
Min: -7.39  Med: 12.05 Max: 17.34
Current: 6.39
-7.39
17.34
ROC (Joel Greenblatt) % 35.61
LLY's ROC (Joel Greenblatt) % is ranked higher than
73% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. LLY: 35.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LLY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10.98  Med: 52.57 Max: 71.98
Current: 35.61
-10.98
71.98
3-Year Revenue Growth Rate -2.10
LLY's 3-Year Revenue Growth Rate is ranked lower than
74% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. LLY: -2.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LLY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.7  Med: 6.9 Max: 14.3
Current: -2.1
-5.7
14.3
3-Year EBITDA Growth Rate -9.40
LLY's 3-Year EBITDA Growth Rate is ranked lower than
80% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. LLY: -9.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LLY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -76.9  Med: 2.4 Max: 437.2
Current: -9.4
-76.9
437.2
3-Year EPS without NRI Growth Rate -15.80
LLY's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. LLY: -15.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LLY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.4  Med: 2.8 Max: 54.9
Current: -15.8
-26.4
54.9
GuruFocus has detected 6 Warning Signs with Eli Lilly and Co $LLY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LLY's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

LLY Guru Trades in Q3 2016

John Paulson 45,800 sh (New)
Jeremy Grantham 1,047,310 sh (+6.38%)
Ken Fisher 2,096,406 sh (+5.62%)
Sarah Ketterer 2,313,413 sh (+3.60%)
Eaton Vance Worldwide Health Sciences Fund 881,915 sh (+44.34%)
Vanguard Health Care Fund 25,959,710 sh (unchged)
David Dreman 900 sh (unchged)
Dodge & Cox 29,332 sh (unchged)
HOTCHKIS & WILEY 26,900 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
John Burbank 1,500,000 sh (unchged)
John Hussman Sold Out
Caxton Associates Sold Out
Mario Gabelli 82,050 sh (-0.85%)
PRIMECAP Management 56,449,048 sh (-1.74%)
Mairs and Power 242,170 sh (-1.98%)
Murray Stahl 28,616 sh (-4.83%)
Pioneer Investments 759,117 sh (-5.28%)
Manning & Napier Advisors, Inc 19,986 sh (-12.21%)
Paul Tudor Jones 8,100 sh (-28.60%)
Andreas Halvorsen 6,092,264 sh (-35.03%)
Jim Simons 922,200 sh (-57.91%)
Ray Dalio 19,881 sh (-74.33%)
Steven Cohen 308,400 sh (-77.16%)
» More
Q4 2016

LLY Guru Trades in Q4 2016

Joel Greenblatt 38,305 sh (New)
Ray Dalio 119,400 sh (+500.57%)
Paul Tudor Jones 18,158 sh (+124.17%)
Pioneer Investments 1,374,165 sh (+81.02%)
Jim Simons 1,539,200 sh (+66.91%)
Sarah Ketterer 3,101,165 sh (+34.05%)
Manning & Napier Advisors, Inc 22,216 sh (+11.16%)
Ken Fisher 2,314,764 sh (+10.42%)
Vanguard Health Care Fund 27,339,210 sh (+5.31%)
Jeremy Grantham 1,085,111 sh (+3.61%)
Mairs and Power 250,478 sh (+3.43%)
PRIMECAP Management 57,501,098 sh (+1.86%)
HOTCHKIS & WILEY 26,900 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 881,915 sh (unchged)
David Dreman Sold Out
John Paulson Sold Out
Andreas Halvorsen Sold Out
Mario Gabelli 80,550 sh (-1.83%)
Dodge & Cox 28,597 sh (-2.51%)
Murray Stahl 26,616 sh (-6.99%)
Steven Cohen 6,900 sh (-97.76%)
» More
Q1 2017

LLY Guru Trades in Q1 2017

George Soros 3,900 sh (New)
Steven Cohen 902,600 sh (+12981.16%)
Joel Greenblatt 448,591 sh (+1071.10%)
Mairs and Power 719,208 sh (+187.13%)
Jim Simons 2,980,400 sh (+93.63%)
Manning & Napier Advisors, Inc 27,277 sh (+22.78%)
Ken Fisher 2,581,462 sh (+11.52%)
HOTCHKIS & WILEY 26,900 sh (unchged)
Steven Cohen 100,000 sh (unchged)
Ray Dalio Sold Out
PRIMECAP Management 57,129,705 sh (-0.65%)
Vanguard Health Care Fund 27,091,270 sh (-0.91%)
Mario Gabelli 79,100 sh (-1.80%)
Pioneer Investments 1,306,010 sh (-4.96%)
Dodge & Cox 26,997 sh (-5.59%)
Murray Stahl 25,091 sh (-5.73%)
Sarah Ketterer 2,405,934 sh (-22.42%)
Jeremy Grantham 838,219 sh (-22.75%)
Paul Tudor Jones 4,000 sh (-77.97%)
Eaton Vance Worldwide Health Sciences Fund 792,297 sh (-10.16%)
» More
Q2 2017

LLY Guru Trades in Q2 2017

Ray Dalio 51,151 sh (New)
Dodge & Cox 5,991,952 sh (+22094.88%)
Jim Simons 5,694,905 sh (+91.08%)
Steven Cohen 1,278,149 sh (+41.61%)
Sarah Ketterer 3,269,253 sh (+35.88%)
Mairs and Power 871,836 sh (+21.22%)
Ken Fisher 2,989,521 sh (+15.81%)
Vanguard Health Care Fund 28,073,170 sh (+3.62%)
Jeremy Grantham 867,273 sh (+3.47%)
Murray Stahl 25,447 sh (+1.42%)
HOTCHKIS & WILEY 26,900 sh (unchged)
George Soros Sold Out
PRIMECAP Management 56,362,580 sh (-1.34%)
Mario Gabelli 76,800 sh (-2.91%)
Manning & Napier Advisors, Inc 24,802 sh (-9.07%)
Paul Tudor Jones 2,968 sh (-25.80%)
Pioneer Investments 937,650 sh (-28.20%)
Joel Greenblatt 8,999 sh (-97.99%)
Eaton Vance Worldwide Health Sciences Fund 645,890 sh (-18.48%)
» More
» Details

Insider Trades

Latest Guru Trades with LLY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Add 3.62%0.17%$76.98 - $86.25 $ 77.38-5%28,073,170
Dodge & Cox 2017-06-30 Add 22094.88%0.42%$76.98 - $86.25 $ 77.38-5%5,991,952
Ken Fisher 2017-06-30 Add 15.81%0.05%$76.98 - $86.25 $ 77.38-5%2,989,521
Mario Gabelli 2017-06-30 Reduce -2.91%$76.98 - $86.25 $ 77.38-5%76,800
Joel Greenblatt 2017-06-30 Reduce -97.99%0.47%$76.98 - $86.25 $ 77.38-5%8,999
George Soros 2017-06-30 Sold Out 0.01%$76.98 - $86.25 $ 77.38-5%0
Vanguard Health Care Fund 2017-03-31 Reduce -0.91%0.04%$74.58 - $85.88 $ 77.38-3%27,091,270
Ken Fisher 2017-03-31 Add 11.52%0.04%$74.58 - $85.88 $ 77.38-3%2,581,462
Joel Greenblatt 2017-03-31 Add 1071.10%0.44%$74.58 - $85.88 $ 77.38-3%448,591
Mario Gabelli 2017-03-31 Reduce -1.80%$74.58 - $85.88 $ 77.38-3%79,100
Dodge & Cox 2017-03-31 Reduce -5.59%$74.58 - $85.88 $ 77.38-3%26,997
George Soros 2017-03-31 New Buy0.01%$74.58 - $85.88 $ 77.38-3%3,900
Vanguard Health Care Fund 2016-12-31 Add 5.31%0.24%$65.97 - $83.06 $ 77.384%27,339,210
Ken Fisher 2016-12-31 Add 10.42%0.03%$65.97 - $83.06 $ 77.384%2,314,764
Mario Gabelli 2016-12-31 Reduce -1.83%$65.97 - $83.06 $ 77.384%80,550
Joel Greenblatt 2016-12-31 New Buy0.04%$65.97 - $83.06 $ 77.384%38,305
Dodge & Cox 2016-12-31 Reduce -2.51%$65.97 - $83.06 $ 77.384%28,597
David Dreman 2016-12-31 Sold Out 0.04%$65.97 - $83.06 $ 77.384%0
John Paulson 2016-12-31 Sold Out 0.04%$65.97 - $83.06 $ 77.384%0
Ken Fisher 2016-09-30 Add 5.62%0.02%$76.85 - $83.4 $ 77.38-3%2,096,406
Mario Gabelli 2016-09-30 Reduce -0.85%$76.85 - $83.4 $ 77.38-3%82,050
John Paulson 2016-09-30 New Buy0.04%$76.85 - $83.4 $ 77.38-3%45,800
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:BMY, NYSE:ABBV, NYSE:MRK, NAS:AERI, AMEX:TXMD, NAS:RTRX, NAS:RMTI, NAS:ZGNX, NAS:ALIM, AMEX:NNVC, NAS:PRPH, AMEX:AXN, NAS:TNXP, OTCPK:INNV, NAS:ALQA, NAS:IMNP, OTCPK:INBP, OTCPK:ENZB, NYSE:PFE, NYSE:JNJ » details
Traded in other countries:LLY.Argentina, LILY34.Brazil, LLY.France, LLY.Germany, LLY.Mexico, LLY.Switzerland, LEL.UK,
Headquarter Location:USA
Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.

Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Humalog, and Humulin for diabetes; and Cialis for erectile dysfunction. Also, Lilly holds a strong position in the animal healthcare market.

Top Ranked Articles about Eli Lilly and Co

3 Companies Aiming to Significantly Reduce Diabetes Treatment Costs Diabetes accounts for nearly 10% of US health care spending
Total U.S. health care spending in 2015 was an astronomical $3.2 trillion. That is 16% of the entire national debt. As much as we blame the prices of new drugs for this gargantuan sum, one of the biggest chunks of it comes from diabetes, a disease whose treatment has not changed all that much since 1922. According to the American Diabetes Association, diabetes accounts for $322 billion in total U.S. health care spending as of 2016. Read more...
Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine
Vanguard Health Care Fund Adds to Multiple Positions The fund built up many positions in the 2nd quarter
The Vanguard Health Care Fund (Trades, Portfolio) increased its holdings of many stocks during the quarter. The eight largest are as follows. Read more...
Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes
A Look at the Science Underpinning the Nektar-Eli Lily Collaboration Here's what's important from a scientific perspective
On July 24, Nektar Therapeutics Inc. (NASDAQ:NKTR) announced it had struck a deal with pharma giant Eli Lilly and Co. (NYSE:LLY). The deal, worth $150 million, will see the two companies join hands in an effort to develop a drug called NKTR-358. It is a very early-stage asset and the upfront payment ranks it as one of the largest in biotech history for an asset at this stage of development (the drug is in a phase I currently that is yet to complete). Read more...
Lilly and Incyte Provide Update on Baricitinib
Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy
Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation
Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017)
Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment

Ratios

vs
industry
vs
history
PE Ratio 33.50
LLY's PE Ratio is ranked lower than
69% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.93 vs. LLY: 33.50 )
Ranked among companies with meaningful PE Ratio only.
LLY' s PE Ratio Range Over the Past 10 Years
Min: 7.44  Med: 16.34 Max: 45.75
Current: 33.5
7.44
45.75
Forward PE Ratio 18.52
LLY's Forward PE Ratio is ranked lower than
57% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.90 vs. LLY: 18.52 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 33.50
LLY's PE Ratio without NRI is ranked lower than
68% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.21 vs. LLY: 33.50 )
Ranked among companies with meaningful PE Ratio without NRI only.
LLY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.44  Med: 16.34 Max: 45.75
Current: 33.5
7.44
45.75
Price-to-Owner-Earnings 26.05
LLY's Price-to-Owner-Earnings is ranked higher than
58% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.90 vs. LLY: 26.05 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LLY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.36  Med: 14.13 Max: 159.16
Current: 26.05
6.36
159.16
PB Ratio 6.05
LLY's PB Ratio is ranked lower than
83% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. LLY: 6.05 )
Ranked among companies with meaningful PB Ratio only.
LLY' s PB Ratio Range Over the Past 10 Years
Min: 2.52  Med: 4.17 Max: 6.85
Current: 6.05
2.52
6.85
PS Ratio 3.73
LLY's PS Ratio is ranked lower than
61% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. LLY: 3.73 )
Ranked among companies with meaningful PS Ratio only.
LLY' s PS Ratio Range Over the Past 10 Years
Min: 1.49  Med: 2.69 Max: 4.81
Current: 3.73
1.49
4.81
Price-to-Free-Cash-Flow 21.63
LLY's Price-to-Free-Cash-Flow is ranked higher than
52% of the 208 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. LLY: 21.63 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LLY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.17  Med: 13.56 Max: 56.76
Current: 21.63
5.17
56.76
Price-to-Operating-Cash-Flow 14.50
LLY's Price-to-Operating-Cash-Flow is ranked higher than
57% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.02 vs. LLY: 14.50 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LLY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.41  Med: 10.95 Max: 31.12
Current: 14.5
4.41
31.12
EV-to-EBIT 27.23
LLY's EV-to-EBIT is ranked lower than
71% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. LLY: 27.23 )
Ranked among companies with meaningful EV-to-EBIT only.
LLY' s EV-to-EBIT Range Over the Past 10 Years
Min: -303.9  Med: 11.9 Max: 37.4
Current: 27.23
-303.9
37.4
EV-to-EBITDA 18.79
LLY's EV-to-EBITDA is ranked lower than
61% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. LLY: 18.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
LLY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.8  Med: 11.6 Max: 1132
Current: 18.79
4.8
1132
Shiller PE Ratio 25.68
LLY's Shiller PE Ratio is ranked higher than
67% of the 198 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.37 vs. LLY: 25.68 )
Ranked among companies with meaningful Shiller PE Ratio only.
LLY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.87  Med: 18.35 Max: 29.2
Current: 25.68
10.87
29.2
Current Ratio 1.39
LLY's Current Ratio is ranked lower than
81% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. LLY: 1.39 )
Ranked among companies with meaningful Current Ratio only.
LLY' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.58 Max: 3
Current: 1.39
0.7
3
Quick Ratio 1.01
LLY's Quick Ratio is ranked lower than
82% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. LLY: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
LLY' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 1.22 Max: 2.38
Current: 1.01
0.53
2.38
Days Inventory 248.80
LLY's Days Inventory is ranked lower than
89% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. LLY: 248.80 )
Ranked among companies with meaningful Days Inventory only.
LLY' s Days Inventory Range Over the Past 10 Years
Min: 173.48  Med: 209.47 Max: 229.6
Current: 248.8
173.48
229.6
Days Sales Outstanding 72.15
LLY's Days Sales Outstanding is ranked higher than
57% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. LLY: 72.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
LLY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.79  Med: 54.75 Max: 69.3
Current: 72.15
49.79
69.3
Days Payable 79.86
LLY's Days Payable is ranked higher than
55% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.96 vs. LLY: 79.86 )
Ranked among companies with meaningful Days Payable only.
LLY' s Days Payable Range Over the Past 10 Years
Min: 73.87  Med: 83.36 Max: 96.97
Current: 79.86
73.87
96.97

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.66
LLY's Dividend Yield % is ranked higher than
85% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. LLY: 2.66 )
Ranked among companies with meaningful Dividend Yield % only.
LLY' s Dividend Yield % Range Over the Past 10 Years
Min: 2.24  Med: 3.62 Max: 6.79
Current: 2.66
2.24
6.79
Dividend Payout Ratio 0.89
LLY's Dividend Payout Ratio is ranked lower than
83% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. LLY: 0.89 )
Ranked among companies with meaningful Dividend Payout Ratio only.
LLY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.43  Med: 0.54 Max: 0.89
Current: 0.89
0.43
0.89
3-Year Dividend Growth Rate 1.30
LLY's 3-Year Dividend Growth Rate is ranked lower than
65% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. LLY: 1.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
LLY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7 Max: 20.2
Current: 1.3
0
20.2
Forward Dividend Yield % 2.70
LLY's Forward Dividend Yield % is ranked higher than
69% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. LLY: 2.70 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.77
LLY's 5-Year Yield-on-Cost % is ranked higher than
72% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. LLY: 2.77 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
LLY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.33  Med: 3.77 Max: 7.07
Current: 2.77
2.33
7.07
3-Year Average Share Buyback Ratio 0.50
LLY's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 473 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. LLY: 0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LLY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: -0.1 Max: 2
Current: 0.5
-3.1
2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 16.21
LLY's Price-to-Tangible-Book is ranked lower than
93% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.51 vs. LLY: 16.21 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LLY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.22  Med: 6.67 Max: 33.46
Current: 16.21
3.22
33.46
Price-to-Intrinsic-Value-Projected-FCF 1.79
LLY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
58% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. LLY: 1.79 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LLY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.68  Med: 2.1 Max: 5.56
Current: 1.79
0.68
5.56
Price-to-Median-PS-Value 1.38
LLY's Price-to-Median-PS-Value is ranked lower than
74% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. LLY: 1.38 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LLY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.6  Med: 1.48 Max: 4
Current: 1.38
0.6
4
Price-to-Graham-Number 4.92
LLY's Price-to-Graham-Number is ranked lower than
90% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. LLY: 4.92 )
Ranked among companies with meaningful Price-to-Graham-Number only.
LLY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.25  Med: 2.76 Max: 8.41
Current: 4.92
1.25
8.41
Earnings Yield (Greenblatt) % 3.67
LLY's Earnings Yield (Greenblatt) % is ranked higher than
50% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. LLY: 3.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LLY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.9  Med: 6.9 Max: 17.4
Current: 3.67
-2.9
17.4
Forward Rate of Return (Yacktman) % -5.98
LLY's Forward Rate of Return (Yacktman) % is ranked lower than
82% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. LLY: -5.98 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LLY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -17  Med: 5 Max: 72
Current: -5.98
-17
72

More Statistics

Revenue (TTM) (Mil) $22,004.80
EPS (TTM) $ 2.31
Beta0.15
Short Percentage of Float1.06%
52-Week Range $64.18 - 86.72
Shares Outstanding (Mil)1,100.99

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 22,645 23,398 23,348
EPS ($) 4.16 4.56 4.95
EPS without NRI ($) 4.16 4.56 4.95
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.68%
Dividends per Share ($) 2.12 2.27 2.29
» More Articles for LLY

Headlines

Articles On GuruFocus.com
Wells Fargo: Hedge Funds' Most Loved Stock Aug 04 2017 
Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of M Aug 04 2017 
Vanguard Health Care Fund Adds to Multiple Positions Aug 01 2017 
Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight th Jul 31 2017 
A Look at the Science Underpinning the Nektar-Eli Lily Collaboration Jul 26 2017 
Lilly and Incyte Provide Update on Baricitinib Jul 25 2017 
Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoi Jul 24 2017 
United Therapeutics Exhibits Some Value Jul 20 2017 
Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation Jul 12 2017 
Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Jul 12 2017 

More From Other Websites
Eli Lilly: Can Sales Grow Without M&A? Aug 18 2017
Opdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017 Aug 18 2017
Eli Lilly: Will A New Rival Hobble Its Top Growth Driver? Aug 17 2017
Novo Nordisk's diabetes drug succeeds in key trial (Aug 16) Aug 17 2017
See what the IHS Markit Score report has to say about Eli Lilly And Co. Aug 16 2017
ETFs with exposure to Eli Lilly & Co. : August 14, 2017 Aug 14 2017
What Trump has done to lower the ‘RIPOFF DRUG PRICES’ he’s decrying Aug 14 2017
Will Nektar's (NKTR) Candidates Enhance Growth in 2017? Aug 14 2017
Edited Transcript of LLY earnings conference call or presentation 25-Jul-17 1:00pm GMT Aug 13 2017
Pfizer’s Valuation after 2Q17 Earnings Aug 11 2017
Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag Aug 11 2017
The Zacks Analyst Blog Highlights: Eli Lilly, Halliburton, Monster Beverage, Huntington Bancshares... Aug 11 2017
Top Research Reports for Eli Lilly, Halliburton & Monster Beverage Aug 10 2017
CVS Health's dull Q3 forecast overshadows profit beat Aug 08 2017
Can CVS Health Corp (CVS) Stock Stop Infuriating the Bulls? Aug 07 2017
Q2 Earnings Fail to Impress Pharma ETF Aug 07 2017
Featured Company News - Eli Lilly Achieves Positive Results for Second Phase-3 Study of Lasmiditan,... Aug 07 2017
[$$] CVS Formulary Changes Boost JNJ, Pfizer; Hurt Lilly Aug 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}